» Articles » PMID: 39772044

Advantages of Broad-Spectrum Influenza MRNA Vaccines and Their Impact on Pulmonary Influenza

Overview
Date 2025 Jan 8
PMID 39772044
Authors
Affiliations
Soon will be listed here.
Abstract

Influenza poses a significant global health challenge due to its rapid mutation and antigenic variability, which often leads to seasonal epidemics and frequent outbreaks. Traditional vaccines struggle to offer comprehensive protection because of mismatches with circulating viral strains. The development of a broad-spectrum vaccine is therefore crucial. This paper explores the potential of mRNA vaccine technology to address these challenges by providing a swift, adaptable, and broad protective response against evolving influenza strains. We detail the mechanisms of antigenic variation in influenza viruses and discuss the rapid design and production, enhanced immunogenicity, encoding of multiple antigens, and safety and stability of mRNA vaccines compared to traditional methods. By leveraging these advantages, mRNA vaccines represent a revolutionary approach in influenza prevention, potentially offering broad-spectrum protection and significantly improving global influenza management and response strategies.

References
1.
Banyard A, Bennison A, Byrne A, Reid S, Lynton-Jenkins J, Mollett B . Detection and spread of high pathogenicity avian influenza virus H5N1 in the Antarctic Region. Nat Commun. 2024; 15(1):7433. PMC: 11372179. DOI: 10.1038/s41467-024-51490-8. View

2.
Chaudhary N, Weissman D, Whitehead K . mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov. 2021; 20(11):817-838. PMC: 8386155. DOI: 10.1038/s41573-021-00283-5. View

3.
Petrovsky N, Aguilar J . Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004; 82(5):488-96. DOI: 10.1111/j.0818-9641.2004.01272.x. View

4.
Boni M, de Jong M, van Doorn H, Holmes E . Guidelines for identifying homologous recombination events in influenza A virus. PLoS One. 2010; 5(5):e10434. PMC: 2862710. DOI: 10.1371/journal.pone.0010434. View

5.
Rabu C, Rangan L, Florenceau L, Fortun A, Charpentier M, Dupre E . Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells. Oncoimmunology. 2019; 8(4):e1560919. PMC: 6422379. DOI: 10.1080/2162402X.2018.1560919. View